Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Expands By 187.2%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large increase in short interest in May. As of May 15th, there was short interest totaling 70,108 shares, an increase of 187.2% from the April 30th total of 24,410 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 92,510 shares, the short-interest ratio is currently 0.8 days.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Lixte Biotechnology Price Performance

Shares of LIXT traded up $0.26 during mid-day trading on Friday, reaching $6.25. The company had a trading volume of 40,306 shares, compared to its average volume of 102,991. Lixte Biotechnology has a twelve month low of $0.64 and a twelve month high of $6.50. The company’s 50-day moving average is $4.01 and its 200-day moving average is $3.74. The company has a market capitalization of $77.39 million, a P/E ratio of -5.53 and a beta of 1.04.

Lixte Biotechnology (NASDAQ:LIXT) last issued its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

A number of hedge funds have recently modified their holdings of the stock. Axxcess Wealth Management LLC acquired a new position in shares of Lixte Biotechnology in the 4th quarter worth approximately $54,000. XTX Topco Ltd acquired a new position in shares of Lixte Biotechnology in the 4th quarter worth approximately $57,000. Federation des caisses Desjardins du Quebec raised its holdings in shares of Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after buying an additional 42,530 shares in the last quarter. DRW Securities LLC raised its holdings in shares of Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after buying an additional 5,645 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Lixte Biotechnology by 47.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after buying an additional 34,350 shares in the last quarter. 5.10% of the stock is owned by institutional investors and hedge funds.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.